499 related articles for article (PubMed ID: 32926459)
21. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
22. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.
Tsujikawa LM; Kharenko OA; Stotz SC; Rakai BD; Sarsons CD; Gilham D; Wasiak S; Fu L; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Biomed Pharmacother; 2022 Aug; 152():113230. PubMed ID: 35687908
[TBL] [Abstract][Full Text] [Related]
23. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK
J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.
Wang Z; Yin L; Xiong Z; Huang F; Yang N; Jiang F; Li H; Cui Y; Ren J; Cheng Z; Jia K; Lu T; Zhu J; Hu Q; Chen Y
J Med Chem; 2023 Aug; 66(15):10824-10848. PubMed ID: 37478496
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
26. Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics.
Ma Z; Bolinger AA; Zhou J; Tian B
Expert Opin Ther Targets; 2023 Jan; 27(1):1-7. PubMed ID: 36710583
[TBL] [Abstract][Full Text] [Related]
27. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
28. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
29. Discovery of BET specific bromodomain inhibitors with a novel scaffold.
Pandit N; Yoo M; Hyun Park T; Kim J; Mi Kim S; Myung Lee K; Kim Y; Min Bong S; Il Lee B; Jung KY; Hoon Park C
Bioorg Med Chem; 2022 Oct; 72():116967. PubMed ID: 36099719
[TBL] [Abstract][Full Text] [Related]
30. [Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].
Gao RL; Zeng CW; Li YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1365-1368. PubMed ID: 34362532
[TBL] [Abstract][Full Text] [Related]
31. Physachenolide C is a Potent, Selective BET Inhibitor.
Zerio CJ; Sivinski J; Wijeratne EMK; Xu YM; Ngo DT; Ambrose AJ; Villa-Celis L; Ghadirian N; Clarkson MW; Zhang DD; Horton NC; Gunatilaka AAL; Fromme R; Chapman E
J Med Chem; 2023 Jan; 66(1):913-933. PubMed ID: 36577036
[TBL] [Abstract][Full Text] [Related]
32. The Functions of BET Proteins in Gene Transcription of Biology and Diseases.
Cheung KL; Kim C; Zhou MM
Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900
[TBL] [Abstract][Full Text] [Related]
33. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
34. Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor.
Chauhan J; Yoshioka M; Pogash S; Strovel JW; Fletcher S
Bioorg Med Chem Lett; 2023 Apr; 86():129220. PubMed ID: 36905966
[TBL] [Abstract][Full Text] [Related]
35. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
38. BET proteins: Biological functions and therapeutic interventions.
Guo J; Zheng Q; Peng Y
Pharmacol Ther; 2023 Mar; 243():108354. PubMed ID: 36739915
[TBL] [Abstract][Full Text] [Related]
39. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
Liang D; Yu Y; Ma Z
Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
[TBL] [Abstract][Full Text] [Related]
40. KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity.
Qiang Y; Fan J; Xie C; Yan L; Song X; Zhang N; Lin Y; Xiong J; Zhang W; Liu Y; Wei L; Li Y; Chen S; Liang K; Li F
Cancer Res; 2024 Apr; 84(8):1252-1269. PubMed ID: 38285760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
